These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 22076546)
1. Intrathecal effects of daclizumab treatment of multiple sclerosis. Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546 [TBL] [Abstract][Full Text] [Related]
2. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933 [TBL] [Abstract][Full Text] [Related]
3. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW; Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990 [TBL] [Abstract][Full Text] [Related]
4. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry. Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA Front Immunol; 2020; 11():714. PubMed ID: 32391016 [TBL] [Abstract][Full Text] [Related]
6. CNS vasculitis in a patient with MS on daclizumab monotherapy. Ohayon J; Oh U; Richert N; Martin J; Vortmeyer A; McFarland H; Bielekova B Neurology; 2013 Jan; 80(5):453-7. PubMed ID: 23303850 [TBL] [Abstract][Full Text] [Related]
8. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. Giovannoni G; Radue EW; Havrdova E; Riester K; Greenberg S; Mehta L; Elkins J J Neurol; 2014 Feb; 261(2):316-23. PubMed ID: 24375015 [TBL] [Abstract][Full Text] [Related]
9. Daclizumab therapy for multiple sclerosis. Bielekova B Neurotherapeutics; 2013 Jan; 10(1):55-67. PubMed ID: 23055048 [TBL] [Abstract][Full Text] [Related]
10. Daclizumab for relapsing remitting multiple sclerosis. Liu J; Wang LN; Zhan S; Xia Y Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Milo R Ther Adv Neurol Disord; 2014 Jan; 7(1):7-21. PubMed ID: 24409199 [TBL] [Abstract][Full Text] [Related]
12. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463 [TBL] [Abstract][Full Text] [Related]
14. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis. Sheridan JP; Robinson RR; Rose JW Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792 [TBL] [Abstract][Full Text] [Related]
15. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250 [TBL] [Abstract][Full Text] [Related]